How GLP-1 Weight-Loss Drugs Are Transforming the Cannabis Market

The surging popularity of GLP-1 weight-loss drugs is quietly reshaping the $40 billion U.S. cannabis market, according to experts and industry executives. Retailers are adjusting their product offerings to cater to evolving consumer behaviors influenced by these therapies.

Reports from online forums indicate reduced cravings and uncertainties around how GLP-1 treatments may alter marijuana's aftereffects, particularly regarding the appetite-induced 'munchies.' Dispensaries have taken note of changing customer preferences, despite limited scientific data on the matter.

Stoops NYC, a dispensary located in New York's Flatiron district, has begun recommending lower-dose edibles, vapes, or tinctures to customers on GLP-1 medications. One immediate area of concern is digestion, as GLP-1 drugs slow gastric emptying, potentially delaying the effects of edible cannabis and leading users to mistakenly consume larger doses for heightened effects.